Research ArticleTheranostics

Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers

Jean Claude Reubi, Beatrice Waser, Helmut Mäcke and Jean Rivier
Journal of Nuclear Medicine February 2017, 58 (2) 300-306; DOI: https://doi.org/10.2967/jnumed.116.177733

Abstract

There is recent in vitro and in vivo evidence that somatostatin receptor subtype 2 (sst2) antagonists are better tools to target neuroendocrine tumors (NETs) than sst2 agonists. Indeed, antagonists bind to a greater number of sst2 sites than agonists. Whether sst2 antagonists could be used successfully to target non-NETs, expressing low sst2 density, is unknown. Here, we compare quantitatively 125I-JR11 sst2 antagonist binding in vitro with that of the sst2 agonist 125I-Tyr3-octreotide in large varieties of non-NET and NET. Methods: In vitro receptor autoradiography was performed with 125I-JR11 and 125I-Tyr3-octreotide in cancers from prostate, breast, colon, kidney, thyroid, and lymphoid tissues as well as NETs as reference. Results: In general, 125I-JR11 binds to many more sst2 sites than 125I-Tyr3-octreotide. In 13 breast cancers, 8 had a low binding (mean density, 844 ± 168 dpm/mg of tissue) with the agonist whereas 12 had a high binding (mean density, 4,447 ± 1,128 dpm/mg of tissue) with the antagonist. All 12 renal cell cancers showed a low binding of sst2 with the agonist (mean density, 348 ± 49 dpm/mg of tissue) whereas all cases had a high sst2 binding with the antagonist (mean density, 3,777 ± 582 dpm/mg of tissue). One of 5 medullary thyroid cancers was positive with the agonist, whereas 5 of 5 were positive with the antagonist. In 15 non-Hodgkin lymphomas, many more sst2 sites were labeled with the antagonist than with the agonist. In 14 prostate cancers, none had sst2 binding with the agonist and only 4 had a weak binding with the antagonist. None of 17 colon cancers showed sst2 sites with the agonist, and only 3 cases were weakly positive with the antagonist. In the various tumor types, adjacent sst2-expressing tissues such as vessels, lymphocytes, nerves, mucosa, or stroma were more strongly labeled with the antagonist than with the agonist. The reference NET cases, incubated with a smaller amount of tracer, were also found to have many more sst2 sites measured with the antagonist. Conclusion: All renal cell cancers and most breast cancers, non-Hodgkin lymphomas, and medullary thyroid cancers represent novel indications for the in vivo radiopeptide targeting of sst2 by sst2 antagonists, comparable to NET radiotargeting with sst2 agonists.

Somatostatin receptors (sst) are highly overexpressed in gastroenteropancreatic and extra-gastrointestinal neuroendocrine tumors (NETs). This represents the molecular basis for sst-targeted diagnostic and therapeutic procedures in NET patients with somatostatin analogs (1–3). One main clinical application makes use of the inhibitory effects of somatostatin on NET cells, particularly on hormone secretion: long-acting somatostatin analogs, such as octreotide or lanreotide, potently inhibit tumoral hormone secretion and improve related symptoms. The second targeting approach is based on the administration of radioactive somatostatin analogs for diagnostic or therapeutic purposes. Indeed, 111In-octreotide scintigraphy (OctreoScan; Mallinckrodt) and other sst subtype 2 (sst2)–targeted imaging with, for example, 68Ga-DOTATATE, are gold standard methods for NET detection. Moreover, sst radionuclide therapy of NET with 90Y- or 177Lu-labeled somatostatin analogs is highly effective and increasingly applied (4,5). Recently, results of the first prospective, randomized, controlled phase III study using radiolabeled somatostatin analogs for peptide receptor radiotherapy were presented. Lutathera (177Lu-DOTATATE) significantly improved progression-free survival in comparison with cold octreotide therapy in advanced midgut NET (6).

Although it could be shown in vitro that sst2 antagonists do not trigger receptor internalization (7), we could show in animal models that radiolabeled sst2 or sst3 antagonists are not only as good in targeting in vivo the respective receptor, but also even considerably better than the respective agonists (8). The findings that antagonists for G-protein–coupled receptors (GPCRs) recognize more binding sites than agonists are not new and have been discussed in the literature by several groups (9,10). There are only hypotheses in regard to the origin of this difference. The difference is explained by distinct receptor states, those coupling to the G-proteins and uncoupled forms. Antagonists bind to all receptor states whereas agonists bind only to the G-protein–coupled forms that are assumed to represent only a small proportion of the total receptor population (9). In cancer, GPCRs are frequently overexpressed and the superiority of antagonists was shown for the gastrin-releasing peptide receptor (11), sst2 and sst3 (8), and the glucose-dependent insulinotropic polypeptide receptor (12).

A first pilot study in humans using a first-generation sst2 antagonist confirmed the animal studies (13). The antagonists were better than agonists for NET imaging (13). A parallel in vitro study on tissue sections fully confirmed that the 177Lu-DOTA-bass antagonist labeled more sst2 binding sites than the 177Lu-DOTATATE agonist (14). This was observed in NETs but, interestingly, also in a few non-NETs with a low number of sst2 (14). Presently, second-generation sst2 antagonists, such as JR11, are in clinical development, with promising results for diagnosis and targeted radionuclide therapy (15).

In the present study, we aimed at evaluating the in vitro binding properties of the second-generation antagonist JR11, labeled with 125I, and compared it with 125I-Tyr3-octreotide, the standard agonist radioligand (16,17). 125I labeling is the optimal choice for in vitro receptor autoradiography quantification (17,18). Indeed, 125I radioligands have been used for decades for receptor autoradiography measurements, and quantification of the data using radioactive reference standards has been routinely performed (18–20). The present study therefore allows a direct comparison of quantification data with previously published studies using 125I radioligands (18–20). This is at difference with the previous 177Lu-DOTA-bass study (14) in which the data using 177Lu-labeled ligands could not be directly compared with data with 125I-labeled ligands. In the present study, a large number of tumors, including such tumors with high-density sst2 (gastroenteropancreatic NET, pheochromocytomas) and those known to express little or no sst2 (renal cell cancer, breast cancer, prostate cancer, non-Hodgkin lymphoma [NHL], medullary thyroid cancer, colon cancer), were tested with both ligands. Nontumoral tissues, adjacent to the tumors, were also evaluated.

MATERIALS AND METHODS

In a first part, we designed cold iodinated JR-11 (iodo-JR11) (structure: DOTA-Cpa-d-Cys-Aph(L-HOro)-d-Aph(Cbm)-Lys-Thr-Cys d-3-iodo-Tyr-NH2) and measured its binding affinity to sst2. Iodo-JR11 was then tested in a displacement experiment using sst2-transfected cells in an in vitro autoradiography setting with 125I-Tyr3-octreotide as radioligand, as reported previously (21). IC50 (half maximal inhibitory concentration) values were 1.89 ± 1.1 nM (n = 3) for iodo-JR11 and 2.83 ± 1.6 nM (n = 3) for the reference peptide SS-28. The compound iodo-JR11 has therefore high-affinity binding to sst2 and is suitable as radioligand for the planned cancer experiments.

In a second part, we used 125I JR-11 (74,000 GBq [2,000 Ci]/mmol; Anawa) as radioligand to evaluate the presence of sst2 in human breast cancers, renal cell cancers, NHL, medullary thyroid cancers, prostate cancers, colon cancers, pheochromocytomas, paragangliomas, bronchial and ileal NET, and small cell lung cancers. Comparison was done with the agonist tracer 125I-Tyr3-octreotide (74,000 GBq [2,000 Ci]/mmol; Anawa), known to have an IC50 similar to the antagonist (21). Quantification was performed as previously reported (21). Specific binding was calculated as total binding minus nonspecific binding for each tumor case. Nonspecific binding was assessed in each case in an adjacent section incubated with 125I JR-11 or 125I-Tyr3-octreotide in the presence of 100 nM of the unlabeled antagonist or agonist, respectively. The study conformed to the ethical guidelines of the Medical Faculty of the University of Berne. The institutional review board approved this retrospective study and the requirement to obtain informed consent was waived.

RESULTS

One group of tumors, shown previously with sst2 agonist tracers to have low (<1,000 dpm/mg tissue) levels or a lack of sst2, consisting of 13 samples of breast carcinomas, 12 samples of renal cell cancers, 15 samples of NHL, 5 samples of medullary thyroid cancers, 14 samples of prostate cancers, and 17 samples of colon cancers was used in receptor autoradiography experiments as reported previously (22–29). Successive sections were incubated in a buffer solution containing the standard amount of 30,000 cpm/100 μL of 125I-Tyr3-octreotide or 30,000 cpm/100 μL of 125I-JR-11. Quantification was performed as previously reported (21). Tables 1 and 2 and Supplemental Table 1 (supplemental materials are available at http://jnm.snmjournals.org) show all the results.

View this table:
TABLE 1

Comparison of 125I-JR11 Antagonist Binding with 125I-Tyr3-Octreotide Agonist Binding in Breast Cancer and RCCs Using 30,000 cpm/100 μL of Radioligand

View this table:
TABLE 2

Comparison of 125I-JR11 Antagonist Binding with 125I-Tyr3-Octreotide Agonist Binding in Medullary Thyroid Cancers and NHLs Using 30,000 cpm/100 μL of Radioligand

A second group of tumors, shown previously with sst2 agonist tracers to have a high level of sst2, consisting of 5 pheochromocytomas, 2 paragangliomas, 4 ileal NET, 1 bronchial NET, and 4 small cell lung cancers, was also used in receptor autoradiography experiments; however, instead of 30,000 cpm/100 μL of tracer, only 10,000 cpm/100 μL of 125I-Tyr3-octreotide or 125I-JR11 were given. All these cases had been tested previously with 30,000 cpm/100 μL of 125I-Tyr3-octreotide and were shown to express a high density (>2,000 dpm/mg of tissue) of receptors in all cases. The rationale for the strategy to use 10,000 cpm/100 μL of radioligand was that we assumed, based on Cescato et al. (14), that the antagonist tracer binds to more sites than the agonist and that therefore it is mandatory to use a lesser amount of tracer to prevent overexposure of the films in the antagonist part of the experiment. The results are summarized in Table 3.

View this table:
TABLE 3

Comparison of 125I-JR11 Antagonist with 125I-Tyr3-Octreotide Agonist in Selected Tumors with High Density of sst2 Using 10,000 cpm/100 μL of Radioligand

Breast Cancers

Table 1 shows that 8 of 13 breast cancer samples express sst using 125I-Tyr3-octreotide, in most of the cases in low density. The mean density of the receptor-positive cases is 844 ± 168 dpm/mg of tissue (mean ± SEM). These data are comparable with previously reported results (22). With 125I-JR11, however, sst can be detected in as many as 12 of 13 breast cancers, often in high density. The mean density of the receptor-positive cases is 4,447 ± 1,128 dpm/mg of tissue. Figure 1 illustrates the results. Interestingly, although the antagonist labels more sites, the heterogeneity of labeling seen with the agonist is not abolished with the antagonist (Table 1), indicating that breast cancers are multiclonal tumors with areas with and without sst. Moreover, the tumoral and peritumoral vessels in the breast cancer samples are sometimes (4/9 cases) weakly labeled with 125I-Tyr3-octreotide. However, with 125I-JR11, all 9 cases with identified vessels show a moderate to high labeling of these vessels. Therefore, these results are strongly indicative for a markedly higher binding of 125I-JR11 versus 125I-Tyr3-octreotide.

FIGURE 1.
FIGURE 1.

Comparative receptor autoradiography in various cancer types (A, hematoxylin and eosin staining) with 125I-JR11 (B and C) and 125I-Tyr3-octreotide (D and E). B and D are respective total binding, C and E are respective nonspecific binding. Bars = 1 mm. (I) Breast cancer. (II) RCC. (III) Medullary thyroid cancer. (IV) NHL. (V) Colon cancer. In cancers I–V, sections were incubated with 30,000 cpm/100 μL of antagonist or agonist. Cancers I–IV show much higher density of sst2 with antagonist. Colon cancer (V) is negative. (VI) Ileal NET, incubated with 10,000 cpm/100 μL of antagonist or agonist.

Renal Cell Cancers

Table 1 also shows in a series of 12 renal cell cancers a low level of sst with the agonist in all cases; however, a high density of sst can be identified in all cases with the antagonist. One example is shown in Figure 1. Mean density value with the agonist is 348 ± 49 dpm/mg of tissue (mean ± SEM) and 3,777 ± 582 dpm/mg of tissue with the antagonist, representing a more than 10 times difference. The density values with the antagonist resemble the levels seen in NETs in standard studies with the agonist (18–20). As seen previously in breast cancers, a much higher number of binding sites is detected in peritumoral vessels with the antagonist than with the agonist.

Medullary Thyroid Cancers

Table 2 reveals that 4 of 5 medullary thyroid cancers were not labeled with the agonist but that all showed moderate to high labeling with the antagonist. Figure 1 shows a representative example.

NHL

Similarly, Table 2 shows that in the 15 NHLs, the antagonist tracer bound to many more sst2 than the agonist. Whereas the values for the agonist were low or negative, the values measured with the antagonist could be compared with what was seen in NET with the agonist in standard studies (18–20). Figure 1 shows a representative example. Here again, tumoral vessels are strongly positive with the antagonist.

Prostate Cancers

Supplemental Table 1 shows that the agonist 125I-Tyr3-octreotide does not detect any sst2 in the 14 prostate cancer samples, confirming previously published results (23), whereas the antagonist 125I-JR11 detects 5 positive cases, 4 of them having only a low sst2 density. Therefore, the antagonist had a higher sensitivity to detect sst2 in prostate cancer than the agonist. The higher sensitivity was also observed in the normal adjacent prostate tissues, such as stroma, vessels, or nerves: indeed, whereas these tissues were occasionally labeled with 125I-Tyr3-octreotide, as reported previously as well (23), they were labeled to a much higher level in the experiments with 125I-JR11. Figure 2 summarizes these results.

FIGURE 2.
FIGURE 2.

Receptor autoradiography with 125I-JR11 showing sst in a prostate cancer sample. (Left) Hematoxylin and eosin staining. (Middle) Total binding of JR11. (Right) Nonspecific binding. (First row) Weakly receptor-positive prostate cancer. Bar = 1 mm. (Second row) Receptor-positive stroma. Bar = 1 mm. (Third row) Receptor-positive vessels. Bar = 0.1 mm. (Fourth row) Receptor-positive nerve. Bar = 0.1 mm.

Colon Cancers

Supplemental Table 1 also shows that colon cancers in general do not express significant quantities of sst2, either with the agonist or with the antagonist tracer (Fig. 1), except for 3 cases with borderline levels of receptors as measured with the antagonist radioligand; this density is probably not clinically relevant for tumor targeting. However, in approximately half of the agonist experiments, tumoral vessels, lymphatic follicles, and mucosa are labeled as known from previous studies (30); in the antagonist experiments, not only are the vessels, lymphatic follicles, and mucosa labeled in all tested samples, but also the amount of labeling in these compartments is much higher than with the agonist.

NETs

In the series of tumors (Table 3) representing classic indications for sst targeting in vivo, based on the high number of sst, namely pheochromocytomas, paragangliomas, ileal, and bronchial NETs and small cell lung cancers, we have compared agonist and antagonist tracers using a lower amount of tracer of 10,000 cpm/100 μL to prevent overexposure of the films using the antagonist tracer. Despite the lower radioactivity application, the antagonist tracer bound with high levels whereas the agonist tracer bound in general with low levels, as seen in Figure 1. The difference in binding between antagonist and agonist varied between 2.5- and 40-fold.

DISCUSSION

The comparison of the binding of the sst2 agonist 125I-Tyr3-octreotide with the sst2 antagonist 125I-JR11 showed impressively that the antagonist labeled many more sst2 binding sites than the agonist, in tumor cells as well as in adjacent sst2-expressing tissues. The breast cancer data confirm and expand on the receptor quantification aspect of a previous paper (14) showing that a 177Lu-labeled sst2 antagonist labeled more sites than a 177Lu-labeled sst2 agonist. On the basis of the high number of 125I-JR11 binding sites (>2,000 dpm/mg of tissue) in more than half of the tested cases, we conclude in the present study that breast cancers should be added to the list of tumor types that may be successfully targeted in vivo with sst2 antagonist tracers. A similar conclusion can be drawn for renal cell carcinoma (RCC); the antagonist shows a more than 10 times mean increase in sst2 binding than with the agonist. Here, 10 of 12 cases showed an sst2 density higher than 2,000 dpm/mg of tissue. Such values predict a positive sst2 imaging in vivo in patients (18). Therefore, RCCs may be considered a serious indication for radiopeptide targeting with sst2 antagonists. In medullary thyroid cancer and NHL, the antagonist tracer labeled many more sites than the agonist, with 2 of 5 medullary thyroid cancers and 8 of 15 NHLs having an sst2 density over 2,000 dpm/mg of tissue, respectively. The marked differences between agonist and antagonist binding may be explained by G-protein coupling with the receptor, as discussed above. GPCRs were present in at least 2 affinity states for the radioligands, a small proportion in a GPCR conformation can be labeled by agonists, and a large proportion in a G-protein–independent (uncoupled) receptor conformation can be labeled by antagonists (9).

Importantly, in the past, there have been in vivo patient studies using sst2 agonists that documented the possible feasibility of sst2 targeting under certain conditions in several non-NETs or tumors expressing only occasionally sst2 (25–29). Such in vivo studies in patients included targeting of breast cancers (22,31), RCCs (32,33), NHL (34), prostate cancers (24), and medullary thyroid cancers (35). However, as opposed to NETs, there has never been a systematic follow-up and extension of these studies, because it was clear that the predominantly low number of sst2 detected by the agonist radioligands would prevent a routine application of sst2 ligands in these indications.

Other types of cancer tested in the present study do not appear to have a significant number of agonist or antagonist binding sites. Indeed, the prostate cancers are unlikely to be an adequate target for JR11, not only because the tumor cells rarely express sst, but also because adjacent tissues, in particular stroma, vessels, and nerves, regularly express sst that may mimic a tumoral sst2 expression. Similarly, colon cancers seem not to be appropriate tumor types for sst2 radiotargeting, either with sst2 agonists or with antagonists.

For comparison, the tumors with an established high density of sst2, namely the NETs in Table 3, show in all cases a massive overexpression of sst2 with the antagonist, despite the fact that in the present experimental setting the tumor sections were incubated with only one third of the standard radioligand dose. These data confirm what is seen in vivo in patients with gastroenteropancreatic NETs using the sst2 antagonist JR11, as reported by Wild et al. (15). Moreover, not only gastrointestinal NETs but also pheochromocytomas, paragangliomas, and lung NETs may be ideally targeted with sst2 antagonists.

CONCLUSION

Whereas the present in vitro data convincingly show that sst2 antagonists of the second generation such as JR11 are successful and superior to agonists in NETs, the data also strongly suggest that new indications for sst2 targeting with these antagonists should be seriously considered, namely renal cell cancers, breast carcinomas, medullary thyroid cancer, and NHL. These in vitro data provide the molecular basis to initiate a clinical trial in these indications.

DISCLOSURE

Octreopharm Sciences GmbH, Berlin, Germany, provided financial support of a part of the study. Jean Claude Reubi is a consultant to Ipsen and is inventor of several licensed patents. Helmut Mäcke and Jean Rivier are inventors of licensed patents. No other potential conflict of interest relevant to this article was reported.

Acknowledgments

We thank Judit Erchegyi and Charleen Miller for providing technical assistance and Jean Laissue for reviewing selected tumor cases.

Footnotes

  • Published online Aug. 25, 2016.

REFERENCES

  1. 1.↵
    1. Reubi JC
    . Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427.
    OpenUrlCrossRefPubMed
  2. 2.
    1. Oberg KE,
    2. Reubi JC,
    3. Kwekkeboom DJ,
    4. et al
    . Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139:742–753.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ambrosini V,
    2. Fani M,
    3. Fanti S,
    4. et al
    . Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(suppl 2):42S–55S.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kwekkeboom DJ,
    2. de Herder WW,
    3. Kam BL,
    4. et al
    . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–2130.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Imhof A,
    2. Brunner P,
    3. Marincek N,
    4. et al
    . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–2423.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Strosberg J,
    2. Wolin E,
    3. Chasen B,
    4. et al
    . 177-Lu-dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: results of the phase III NETTER-1 trial [abstract]. Eur J Cancer. 2015;51:S710.
    OpenUrl
  7. 7.↵
    1. Waser B,
    2. Tamma ML,
    3. Cescato R,
    4. et al
    . Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50:936–941.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Ginj M,
    2. Zhang H,
    3. Waser B,
    4. et al
    . Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436–16441.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Sleight AJ,
    2. Stam NJ,
    3. Mutel V,
    4. et al
    . Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities. Biochem Pharmacol. 1996;51:71–76.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Perrin MH,
    2. Sutton SW,
    3. Cervini LA,
    4. et al
    . Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther. 1999;288:729–734.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Cescato R,
    2. Maina T,
    3. Nock B,
    4. et al
    . Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318–326.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Hansen LS,
    2. Sparre-Ulrich AH,
    3. Christensen M,
    4. et al
    . N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor. Br J Pharmacol. 2016;173:826–838.
    OpenUrl
  13. 13.↵
    1. Wild D,
    2. Fani M,
    3. Behe M,
    4. et al
    . First clinical evidence that imaging with somatostatin receptor antagonists is clinically feasible. J Nucl Med. 2011;52:1412–1417.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Cescato R,
    2. Waser B,
    3. Fani M,
    4. et al
    . Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52:1886–1890.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Wild D,
    2. Fani M,
    3. Fischer R,
    4. et al
    . Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248–1252.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Reubi JC,
    2. Maurer R,
    3. von Werder K,
    4. et al
    . Somatostatin receptors in human endocrine tumors. Cancer Res. 1987;47:551–558.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Reubi JC,
    2. Kvols LK,
    3. Waser B,
    4. et al
    . Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50:5969–5977.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Reubi JC,
    2. Waser B
    . Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2003;30:781–793.
    OpenUrlCrossRefPubMed
  19. 19.
    1. Körner M,
    2. Waser B,
    3. Reubi JC
    . Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors? Neuroendocrinology. 2015;101:45–57.
    OpenUrl
  20. 20.↵
    1. Reubi JC,
    2. Waser B
    . Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs. J Nucl Med. 2015;56:613–615.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Reubi JC,
    2. Schaer JC,
    3. Waser B,
    4. et al
    . Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–282.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Albérini JL,
    2. Meunier B,
    3. Denzler B,
    4. et al
    . Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat. 2000;61:21–32.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Reubi JC,
    2. Waser B,
    3. Schaer JC,
    4. et al
    . Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab. 1995;80:2806–2814.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Nilsson S,
    2. Reubi JC,
    3. Kalkner K,
    4. et al
    . Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by (111-In)-labeled DTPA-D-(Phe-1)-octreotide scintigraphy. Cancer Res. 1995;55(suppl):5805s–5810s.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Reubi C,
    2. Gugger M,
    3. Waser B
    . Coexpressed peptide receptors in breast cancers as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2002;29:855–862.
    OpenUrlCrossRefPubMed
  26. 26.
    1. Reubi JC,
    2. Mazzucchelli L,
    3. Hennig I,
    4. et al
    . Local upregulation of neuropeptide receptors in host blood vessels around human colorectal cancers. Gastroenterology. 1996;110:1719–1726.
    OpenUrlCrossRefPubMed
  27. 27.
    1. Reubi JC,
    2. Kvols L
    . Somatostatin receptors in human renal cell carcinomas. Cancer Res. 1992;52:6074–6078.
    OpenUrlAbstract/FREE Full Text
  28. 28.
    1. Reubi JC,
    2. Waser B,
    3. van Hagen M,
    4. et al
    . In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer. 1992;50:895–900.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Reubi JC,
    2. Chayvialle JA,
    3. Franc B,
    4. et al
    . Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991;64:567–573.
    OpenUrlPubMed
  30. 30.↵
    1. Reubi JC,
    2. Laissue JA,
    3. Waser B,
    4. et al
    . Expression of somatostatin receptors in normal, inflamed and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci. 1994;733:122–137.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. van Eijck CHJ,
    2. Krenning EP,
    3. Bootsma A,
    4. et al
    . Somatostatin-receptor scintigraphy in primary breast cancer. Lancet. 1994;343:640–643.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Freudenberg LS,
    2. Gauler T,
    3. Gorges R,
    4. et al
    . Somatostatin receptor scintigraphy in advanced renal cell carcinoma: results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC. Nuklearmedizin. 2008;47:127–131.
    OpenUrlPubMed
  33. 33.↵
    1. Peter L,
    2. Sanger J,
    3. Hommann M,
    4. et al
    . Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. Clin Nucl Med. 2014;39:713–716.
    OpenUrl
  34. 34.↵
    1. Vanhagen PM,
    2. Krenning EP,
    3. Reubi JC,
    4. et al
    . Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol. 1993;83:75–79.
    OpenUrlPubMed
  35. 35.↵
    1. Kwekkeboom DJ,
    2. Reubi JC,
    3. Lamberts SWJ,
    4. et al
    . In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76:1413–1417.
    OpenUrlCrossRefPubMed
  • Received for publication May 10, 2016.
  • Accepted for publication August 3, 2016.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Related Articles

Cited By...

More in this TOC Section

Theranostics

Show more Theranostics

Basic

Show more Basic

Similar Articles

Keywords